Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Mayne Pharma Group Ltd (ASX: MYX) has agreed to a takeover bid from Gedeon Richter Plc, with the offer priced at almost double what the company's shares were changing hands for before the deal was announced.

The drug company's shares closed at $3.21 on Monday, 17 November, and the takeover bid is priced at $6.40.

Mayne Pharma shares shot up to $5.71 in early trade on Tuesday, leaving a decent premium of 12.1% to be made if investors buy in and the deal does eventually go through.

Falling pills in a blue background.

Image source: Getty Images

Board and large shareholders back the deal

The deal is being unanimously recommended by the Mayne board. Meanwhile the company's three largest shareholders, Funicular Funds with 9.82%, Bruce Mathieson with 6.46% and Trium Capital with 5.85%, have all indicated they will sell their shares into the deal.

Richter is a specialty pharmaceutical company founded in Hungary 125 years ago, with operations in around 50 countries globally.

The deal is fully funded, Mayne said, and will require approval from Mayne shareholders.

Mayne Chair Bruce Robinson said the deal fulfilled the board's purpose to maximise value for shareholders.

He added:

The Board has carefully considered the proposal from Richter and has unanimously concluded that it is in the best interests of Mayne Pharma shareholders, in the absence of a Superior Proposal and subject to the Independent Expert's conclusion. The Scheme Consideration of $6.40 per share in cash provides shareholders with the opportunity to realise value at a significant premium to recent trading prices and recognises the strength of Mayne Pharma's Women's Health and Dermatology/DistributeRx franchises in the United States.

The deal will be subject to Foreign Investment Review Board approval and is subject to a positive recommendation from an independent expert.

Cosette deal in the rear view mirror

Mayne was the subject of a $7.40 per share takeover bid by US company Cosette, which later tried to back out of the transaction citing a deterioration in Mayne's financial performance.

Mayne took Cosette to court and won a judgment and then a later appeal by Cosette, with the court ruling that, as Mayne said in a statement on 14 October, "no Mayne Material Adverse Change had occurred and that Mayne Pharma did not engage in misleading and deceptive conduct regarding its FY25 EBITDA financial performance''.

Mr Robinson said at the time that Mayne would, "continue to pursue its claims against Cosette, Cosette Pharmaceuticals Holdings, Inc, and its controllers, Mr David Burghstahler and Avista Capital for damages on behalf of itself and Mayne Pharma shareholders''.

The new deal values Mayne's equity at about $604 million.

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »